Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2834 https://altimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune Inc

Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High? - May 23rd, 2022 1:55 pm
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022 - May 20th, 2022 11:30 am
Altimmune to Present at Upcoming Investor Conferences - May 16th, 2022 11:30 am
Altimmune (NASDAQ:ALT) surges 19% this week, taking three-year gains to 111% - May 14th, 2022 1:51 pm
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update - May 12th, 2022 11:00 am
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12 - May 5th, 2022 11:30 am
What Kind Of Investors Own Most Of Altimmune, Inc. (NASDAQ:ALT)? - Apr 1st, 2022 7:40 pm
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity - Apr 1st, 2022 11:00 am
The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider - Mar 22nd, 2022 4:47 pm
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update - Mar 15th, 2022 11:01 am
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 - Mar 8th, 2022 12:00 pm
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for - Feb 17th, 2022 8:02 pm
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity - Jan 31st, 2022 12:00 pm
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation - Jan 28th, 2022 9:36 am
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. - Jan 24th, 2022 7:48 pm
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022 - Jan 3rd, 2022 12:00 pm
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 13th, 2021 11:00 am
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer - Dec 13th, 2021 11:00 am
Altimmune to Present at Upcoming Investor and Scientific Conferences - Nov 22nd, 2021 9:01 pm
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update - Nov 9th, 2021 9:01 pm